Penumbra, Inc. $PEN Shares Bought by Vestmark Advisory Solutions Inc.

Vestmark Advisory Solutions Inc. grew its position in Penumbra, Inc. (NYSE:PEN) by 94.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,640 shares of the company’s stock after buying an additional 795 shares during the period. Vestmark Advisory Solutions Inc.’s holdings in Penumbra were worth $421,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in Penumbra by 0.7% in the first quarter. Vanguard Group Inc. now owns 3,675,349 shares of the company’s stock valued at $982,825,000 after acquiring an additional 24,727 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Penumbra by 437.0% during the first quarter. JPMorgan Chase & Co. now owns 703,634 shares of the company’s stock worth $188,159,000 after acquiring an additional 572,606 shares during the last quarter. Allspring Global Investments Holdings LLC raised its position in Penumbra by 0.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 322,030 shares of the company’s stock valued at $80,726,000 after purchasing an additional 984 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Penumbra by 4.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 283,821 shares of the company’s stock valued at $75,897,000 after purchasing an additional 12,247 shares during the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in shares of Penumbra during the 1st quarter worth $63,731,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on PEN shares. UBS Group set a $335.00 price objective on shares of Penumbra and gave the company a “buy” rating in a report on Wednesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $326.00 price target on shares of Penumbra in a research report on Monday, October 27th. Morgan Stanley upped their price objective on shares of Penumbra from $260.00 to $266.00 and gave the stock an “equal weight” rating in a report on Thursday, July 31st. Wells Fargo & Company set a $290.00 price objective on shares of Penumbra in a research report on Wednesday, October 1st. Finally, Evercore ISI reissued an “outperform” rating and issued a $286.00 target price on shares of Penumbra in a research report on Thursday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat, Penumbra has a consensus rating of “Moderate Buy” and an average price target of $305.69.

Insider Buying and Selling

In related news, Director Thomas Wilder sold 186 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $253.93, for a total transaction of $47,230.98. Following the completion of the transaction, the director directly owned 186 shares of the company’s stock, valued at $47,230.98. The trade was a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Harpreet Grewal sold 186 shares of the company’s stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $227.58, for a total value of $42,329.88. Following the sale, the director owned 8,516 shares in the company, valued at approximately $1,938,071.28. This trade represents a 2.14% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 33,830 shares of company stock valued at $8,848,425. 5.00% of the stock is currently owned by company insiders.

Penumbra Trading Up 3.4%

Shares of PEN stock opened at $279.73 on Wednesday. Penumbra, Inc. has a fifty-two week low of $221.26 and a fifty-two week high of $310.00. The company has a 50 day moving average price of $256.09 and a 200 day moving average price of $258.02. The stock has a market capitalization of $10.95 billion, a P/E ratio of 74.40, a price-to-earnings-growth ratio of 2.10 and a beta of 0.51. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.04 and a current ratio of 6.75.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.90 by $0.07. The company had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. Penumbra had a net margin of 11.54% and a return on equity of 11.55%. The firm’s quarterly revenue was up 17.8% on a year-over-year basis. During the same period in the prior year, the business earned $0.85 EPS. Penumbra has set its FY 2025 guidance at EPS. Equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

About Penumbra

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.